Physician profile
Edith C Roberts
NPI 1194045104
$2,318.52
in general payments reported to CMS, 2019-2025
26 companies · $55.46 in 2025
The $55.46 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $940 · 2023: $1,065 · 2024: $119 · 2025: $55.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.45 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $353.62 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $321.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.40 | 2021-2025 | Farxiga, Breztri, Tezspire |
| Merck Sharp & Dohme LLC | $278.32 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $172.40 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $118.95 | 2022-2023 | |
| Abbvie INC. | $99.05 | 2022-2024 | |
| Evoke Pharma, INC. | $89.47 | 2022-2023 | Gimoti |
| Sumitomo Pharma America, INC. | $88.70 | 2023 | Gemtesa |
| Amgen INC. | $63.40 | 2022-2025 | Otezla, Repatha, Tezspire |
| Otsuka America Pharmaceutical, INC. | $45.26 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.93 | 2021-2023 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $42.17 | 2021-2022 | |
| Astellas Pharma US INC | $41.43 | 2022-2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $40.61 | 2021-2023 | Aralast |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $36.45 | 2023 | Rexulti |
| Novo Nordisk INC | $33.91 | 2022-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $30.75 | 2021-2022 | |
| Exact Sciences Corporation | $21.00 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $20.20 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $17.57 | 2024 | Crysvita |
| Almatica Pharma LLC | $17.10 | 2022 | |
| Glaxosmithkline, LLC. | $15.11 | 2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $13.57 | 2024 | Spravato |
| Genentech USA, INC. | $11.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.